Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 57 of 57 entries
View as:

Phase II Trial GA101 Inbrutinib B CLL

Phase: N/A Priority: Normal
NCT ID: NCT02666898 Org: User:
Start: 10/31/15 End: 09/30/23 Due: 09/30/24

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with P53 Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT03734198 Org: User:
Start: 12/19/18 End: 12/19/25 Due: 12/19/26

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

Phase: N/A Priority: Normal
NCT ID: NCT00564512 Org: User:
Start: 11/30/07 End: 07/31/13 Due: 07/31/14

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Phase: N/A Priority: Normal
NCT ID: NCT02962388 Org: User:
Start: 01/03/17 End: 06/28/21 Due: 06/28/22

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06022003 Org: User:
Start: 01/13/24 End: 10/31/27 Due: 10/31/28

OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06377579 Org: User:
Start: 07/31/24 End: 12/01/25 Due: 12/01/26

Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg

Phase: N/A Priority: Normal
NCT ID: NCT02742324 Org: User:
Start: 03/31/16 End: 12/31/21 Due: 12/31/22